IKZF1 and plasma cell myeloma: In this context, Mougiakakos et al. have demonstrated that the treatment with lenalidomide shifts the phenotype of TAMs, derived from myeloma patients, toward a pro-inflammatory and tumoricidal M1 direction through the IKAROS family zinc finger 1 (IKZF1)-interferon regulatory factor (IRF) 4/5 axis [79].